reference/17368786

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17368786

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	3551
issn	0732-183X 1527-7755
issueIdentifier	21
pageRange	3543-3551
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	3543
bibliographicCitation	Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543–51. doi: 10.1200/jco.2007.15.0375. PMID: 18506025.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2c817b7798e52792c97abcb74691df61 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f4584e170a6e2010c0de583fc440cd6d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_050e829bc730485d4a1626dbbc6b8956 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c072ba8e723f1afb22a004d5c5532236 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a340ba5c8ce9a6c6af1aab01f15ff372 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_65e8d11ea6d2eb9ef8a677f54430110f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_51fec3768a13c0703513b748be555bce http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_454da17192c172a2762715bae713efa2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7aca21b648ef73cee15cca9f1f1d91a4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_72b1bf8ac4e6c4518465994913086fc3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2d8e0dd4da50802b9fa5db326817a4c3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bdde301f6d4dd9313e261b488686fdf7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_87c3ef7945da1838a811172058399109 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5a6cc340d25e8d193e7ea8c5f00e5a31 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_74dd295d62d35ea7121415ed10a52856 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ccd813bb2ca62d6d24b0ce9275f862ab http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9ba5eb988fe9d1f5cdb300f282503159 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f29112ac2f9c74d3c48ca9a03b24d5e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_43f31bd088cef9a1da5eba1c135f24ab http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_03f49cd4b9359d64429e3a2726bfbd07
date	2008-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1200/jco.2007.15.0375 https://pubmed.ncbi.nlm.nih.gov/18506025
isPartOf	https://portal.issn.org/resource/ISSN/0732-183X https://portal.issn.org/resource/ISSN/1527-7755 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
discusses	http://id.nlm.nih.gov/mesh/M0009376 http://id.nlm.nih.gov/mesh/M0004505 http://id.nlm.nih.gov/mesh/M0227083 http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M000754277 http://id.nlm.nih.gov/mesh/M0005997
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D002289Q000188 http://id.nlm.nih.gov/mesh/D008175Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D003841Q000031 http://id.nlm.nih.gov/mesh/D008175Q000473 http://id.nlm.nih.gov/mesh/D008175Q000401 http://id.nlm.nih.gov/mesh/D005971Q000008 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D002945Q000009 http://id.nlm.nih.gov/mesh/D002945Q000008 http://id.nlm.nih.gov/mesh/D003841Q000008 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D003841Q000009 http://id.nlm.nih.gov/mesh/D006147Q000009 http://id.nlm.nih.gov/mesh/D005971Q000009 http://id.nlm.nih.gov/mesh/D002289Q000473 http://id.nlm.nih.gov/mesh/D002289Q000401 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D053208 http://id.nlm.nih.gov/mesh/D000093542 http://id.nlm.nih.gov/mesh/D006147Q000008 http://id.nlm.nih.gov/mesh/D000068437 http://id.nlm.nih.gov/mesh/D006147Q000031 http://id.nlm.nih.gov/mesh/D005260
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6795 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6847 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11445 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10198 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127639621 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129221764 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129439837

Total number of triples: 87.